Inovio begins Phase I trial of INO-5150 DNA immunotherapy to treat prostate cancer
The initiation of this human trial follows strong pre-clinical results revealing that INO-5150 generated healthy CD8+ T cell responses in animal studies including non-human primates. The company noted